Platt D, Bauer M, Eicher H
Institute of Gerontology, University of Erlangen-Nuremberg, FRG.
Arch Gerontol Geriatr. 1989 Mar;8(2):139-50. doi: 10.1016/0167-4943(89)90058-7.
Ranitidine pharmacokinetics was measured after intravenous administration of 50 mg of the drug in 18 geriatric patients suffering from multiple diseases. Elimination half-life was prolonged (3.05 +/- 0.58 h) and total clearance was reduced (282 +/- 97 ml/min) as compared to the results of studies on normal younger persons by other investigators. In comparison to other studies on healthy elderlies, the pharmacokinetic parameters of ranitidine were only slightly different. Statistical analyses showed correlations of pharmacokinetic parameters of ranitidine with creatinine clearance, serum creatinine, uric acid concentration and alkaline phosphatase activity. These results disclose that reduced creatinine clearance or serum creatinine concentration in the upper normal range, for example, might serve as indicators for a possible dose reduction of ranitidine to prevent unnecessary overmedication in elderly patients.
在18名患有多种疾病的老年患者静脉注射50毫克雷尼替丁后，测定了其药代动力学。与其他研究者对正常年轻人的研究结果相比，消除半衰期延长（3.05±0.58小时），总清除率降低（282±97毫升/分钟）。与其他关于健康老年人的研究相比，雷尼替丁的药代动力学参数仅有轻微差异。统计分析表明，雷尼替丁的药代动力学参数与肌酐清除率、血清肌酐、尿酸浓度和碱性磷酸酶活性相关。这些结果表明，例如，肌酐清除率降低或血清肌酐浓度在正常上限范围内，可能作为雷尼替丁可能需要降低剂量的指标，以防止老年患者不必要的用药过量。
